MARKET

FATE

FATE

Fate
NASDAQ

Real-time Quotes | Nasdaq Last Sale

54.29
+1.64
+3.11%
Closed 16:00 11/23 EST
OPEN
53.07
PREV CLOSE
52.65
HIGH
54.95
LOW
52.54
VOLUME
1.30M
TURNOVER
--
52 WEEK HIGH
54.95
52 WEEK LOW
13.26
MARKET CAP
4.74B
P/E (TTM)
-29.4239
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Growth Investors: Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 25%
Fate Therapeutics, Inc. (NASDAQ:FATE) shareholders will have a reason to smile today, with the analysts making...
Simply Wall St. · 11/10 10:54
Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -24.14% and -25.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/05 23:05
Fate Therapeutics EPS misses by $0.36, beats on revenue
Fate Therapeutics (FATE): Q3 GAAP EPS of -$0.68 misses by $0.36.Revenue of $7.56M (+211.1% Y/Y) beats by $0.07M.Press Release
Seekingalpha · 11/05 21:40
Fate Therapeutics Q3 EPS $(0.68) Misses $(0.36) Estimate, Sales $7.56M Beat $6.97M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.36) by 88.89 percent. This is a 70 percent decrease over losses of $(0.40) per share from
Benzinga · 11/05 21:32
Fate Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Fate Therapeutics, Inc.
ACCESSWIRE · 11/05 20:45
Fate Therapeutics Q3 2020 Earnings Preview
Fate Therapeutics (NASDAQ:FATE) is scheduled to announce Q3 earnings results on Thursday, November 5th, after market close.The consensus EPS Estimate is -$0.36 (+10.0% Y/Y) and the consensus Revenue Estimate is
Seekingalpha · 11/04 16:44
Were Hedge Funds Right About Loading Up On Fate Therapeutics Inc (FATE)?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]
Insider Monkey · 11/03 14:15
A Closer Look At Fate Therapeutics
Fate Therapeutics has outperformed many of its peers in the often volatile and risky biotechnology industry.Over the past three years, the stock has soared well over 900%.With an earnings yield of -3.75%, from a value perspective, FATE is not attractive.
Seekingalpha · 10/12 14:40
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FATE. Analyze the recent business situations of Fate through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FATE stock price target is 51.13 with a high estimate of 71.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 274
Institutional Holdings: 91.44M
% Owned: 104.81%
Shares Outstanding: 87.24M
TypeInstitutionsShares
Increased
86
6.40M
New
48
-397.84K
Decreased
64
4.93M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Independent Director
William Rastetter
President/Chief Executive Officer/Director
J. Scott Wolchko
President/Chief Executive Officer/Director
John Wolchko
Vice Chairman/Independent Director
John Mendlein
Chief Financial Officer
Edward Dulac
Senior Vice President
Sarah Cooley
Chief Scientific Officer
Daniel Shoemaker
Vice President
Yu-Waye Chu
General Counsel/Secretary
Cindy Tahl
Other
Bahram Valamehr
Director
Shefali Agarwal
Director
Robert Hershberg
Independent Director
Timothy Coughlin
Independent Director
Robert Epstein
Independent Director
Karin Jooss
Independent Director
Michael Lee
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About FATE
Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Fate Therapeutics Inc stock information, including NASDAQ:FATE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FATE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FATE stock methods without spending real money on the virtual paper trading platform.